LON:ETX

e-therapeutics (ETX) Share Forecast, Price & News

GBX 12.79

-0.06 (-0.47%)

(As of 01:24 PM ET)

Compare

Today's Range: 12.50
▼
12.79
50-Day Range: 12.10
▼
18.03
52-Week Range: 10.05
▼
24

Volume: 64,849 shs
Average Volume: 174,441 shs
Market Capitalization: £74.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About e-therapeutics (LON:ETX) Stock

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

ETX Price History

30 days | 90 days | 365 days | Advanced Chart

ETX Stock News Headlines

September 28, 2023 | benzinga.com

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

September 28, 2023 | marketwatch.com

Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold

September 29, 2023 | Stansberry Research (Ad)

A 73-Year-Old Market Signal With 95% Accuracy Just Flashed

This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.

September 28, 2023 | americanbankingnews.com

e-therapeutics (LON:ETX) Stock Crosses Below 200 Day Moving Average of $16.05

September 20, 2023 | proactiveinvestors.com

e-therapeutics appoints new CFO

September 20, 2023 | americanbankingnews.com

e-therapeutics (LON:ETX) Stock Passes Below 200-Day Moving Average of $16.15

July 13, 2023 | uk.finance.yahoo.com

ETX.L - e-Therapeutics plc

June 8, 2023 | wsj.com

Elicio Therapeutics Inc.

September 29, 2023 | Stansberry Research (Ad)

A 73-Year-Old Market Signal With 95% Accuracy Just Flashed

This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.

May 23, 2023 | businesswire.com

AgeX Therapeutics Announces Appeal of NYSE American Determination

May 10, 2023 | businesswire.com

Rapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian Market

May 10, 2023 | marketwatch.com

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

May 6, 2023 | marketwatch.com

Acute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,Pfizer

May 4, 2023 | marketwatch.com

E-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D Costs

May 4, 2023 | finance.yahoo.com

e-Therapeutics working to capitalise on AI "blindside"

April 28, 2023 | markets.businessinsider.com

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

April 28, 2023 | marketwatch.com

8-K: Seres Therapeutics, Inc.

March 30, 2023 | marketwatch.com

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film to Additional Global Markets

February 26, 2023 | uk.finance.yahoo.com

e-Therapeutics plc (ETX.L)

January 5, 2023 | benzinga.com

Akero Therapeutics Stock (NASDAQ:AKRO), Quotes and News Summary

December 8, 2022 | markets.businessinsider.com

Akero Therapeutics Announces Breakthrough Therapy Designation For Efruxifermin

September 30, 2022 | proactiveinvestors.com

e-therapeutics raises £13.5mln via a direct subscription by funds run by M&G

September 30, 2022 | finance.yahoo.com

e-therapeutics: Fundraise of £13.5 million

September 6, 2022 | finance.yahoo.com

Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

August 21, 2022 | msn.com

WHO recommends monoclonal antibody treatments for Ebola disease

August 4, 2022 | finance.yahoo.com

Companies Like e-therapeutics (LON:ETX) Are In A Position To Invest In Growth

August 3, 2022 | finance.yahoo.com

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

See More Headlines

Receive ETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ETX Company Calendar

Last Earnings: 3/17/2020
Today: 9/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:ETX
CUSIP: N/A
CIK: N/A
Web: www.etherapeutics.co.uk
Phone: +44-1993-880000
Fax: N/A
Employees: 38
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-8,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -27.23%
Return on Assets: -19.95%

Debt

Debt-to-Equity Ratio: 0.89
Current Ratio: 21.30
Quick Ratio: 20.13

Sales & Book Value

Annual Sales: £295,000.00
Price / Sales: 253.13
Cash Flow: GBX 2.52 per share
Price / Cash Flow: 5.07
Book Value: GBX 6 per share
Price / Book: 2.13

Miscellaneous

Outstanding Shares: 583,840,000
Free Float: N/A
Market Cap: £74.67 million
Optionable: Not Optionable
Beta: 0.42

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Ahmad Ali Mortazavi (Age 52)
CEO & Director
Comp: $270k

Mr. Michael Anthony Bretherton ACA (Age 68)
B.A., Interim CFO & Director
Comp: $120k

Dr. Laura Roca-Alonso Ph.D.
Chief Operating Officer

Mr. Alan Whitmore B.Sc.
Ph.D., Chief Scientific Officer

Ms. Sarah Clare
Director of Fin. & Compliance

Ms. Alison Gallafent
Chief Intellectual Property Officer

Mr. Ankit Sharma
Head of Software Engineering

Mr. Graham Craggs
Head of Therapeutic Discovery

Mr. Timothy Bretherton
Director of Fin. & Operations and Company Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ETX Stock - Frequently Asked Questions

How have ETX shares performed in 2023?: e-therapeutics' stock was trading at GBX 16.50 at the beginning of the year. Since then, ETX stock has decreased by 22.5% and is now trading at GBX 12.79.
View the best growth stocks for 2023 here.
How were e-therapeutics' earnings last quarter?: e-therapeutics plc (LON:ETX) announced its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.03.
What other stocks do shareholders of e-therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other e-therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4D pharma (DDDD), Chicken Soup for the Soul Entertainment (CSSE), Crescent Point Energy (CPG), Collagen Solutions plc (COS.L) (COS), BP (BP), Bushveld Minerals (BMN) and Alstom (ALSMY).
What is e-therapeutics' stock symbol?: e-therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."

How do I buy shares of e-therapeutics?: Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is e-therapeutics' stock price today?: One share of ETX stock can currently be purchased for approximately GBX 12.79.
How much money does e-therapeutics make?: e-therapeutics (LON:ETX) has a market capitalization of £74.67 million and generates £295,000.00 in revenue each year. The company earns £-8,270,000.00 in net income (profit) each year or GBX (0.02) on an earnings per share basis.
How can I contact e-therapeutics?: e-therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The official website for the company is www.etherapeutics.co.uk. The company can be reached via phone at +44-1993-880000.

This page (LON:ETX) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial